{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:43:36Z","timestamp":1789163016051,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Septic shock driven by endotoxemia is associated with high mortality despite advances in supportive care. Polymyxin B hemoperfusion (PMX-HP) selectively removes circulating endotoxin and has shown variable efficacy in randomized trials. While earlier studies, such as EUPHAS, suggested benefit, subsequent trials, including ABDO-MIX and EUPHRATES, yielded neutral results, partly due to heterogeneous patient selection. The recently completed TIGRIS trial addressed these limitations by enrolling septic shock patients with intermediate endotoxin activity (EAA: 0.60\u20130.89) and high multiple organ dysfunction syndrome (MODS\u2009&gt;\u20099) using a Bayesian design. In 151 evaluable patients, PMX-HP achieved the primary endpoint, with a 95.3% posterior probability of 28-day survival benefit (adjusted odds ratio [OR]: 0.67; absolute risk reduction [ARR] 6.4%). At 90\u00a0days, mortality reduction was greater (ARR: 17.4%; adjusted OR: 0.54;\u2009&gt;\u200999% posterior probability of benefit), corresponding to a number needed to treat of 8.1. These results support the targeted use of PMX-HP in a biomarker-defined subgroup and may facilitate broader regulatory approval.<\/jats:p>","DOI":"10.1186\/s40560-025-00835-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:15:59Z","timestamp":1764051359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-4088","authenticated-orcid":false,"given":"Toshiaki","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-6800","authenticated-orcid":false,"given":"Julie","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-7406","authenticated-orcid":false,"given":"Isao","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Mineshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-4747","authenticated-orcid":false,"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"1","key":"835_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s13054-023-04690-5","volume":"27","author":"JA Kellum","year":"2023","unstructured":"Kellum JA, Ronco C. The role of endotoxin in septic shock. Crit Care. 2023;27(1):400.","journal-title":"Crit Care"},{"key":"835_CR2","doi-asserted-by":"crossref","unstructured":"Brandenburg K, Schromm AB, Weindl G, Heinbockel L, Correa W, Mauss K, Martinez de Tejada G, Garidel P. An update on endotoxin neutralization strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther. 2021;19(4):495\u2013517.","DOI":"10.1080\/14787210.2021.1834847"},{"issue":"3","key":"835_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1074\/jbc.M504327200","volume":"281","author":"Y Rosenfeld","year":"2006","unstructured":"Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem. 2006;281(3):1636\u201343.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"835_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000356831","volume":"37","author":"C Ronco","year":"2014","unstructured":"Ronco C. Endotoxin removal: history of a mission. Blood Purif. 2014;37(Suppl 1):5\u20138.","journal-title":"Blood Purif"},{"issue":"2","key":"835_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/ags3.12015","volume":"1","author":"T Shimizu","year":"2017","unstructured":"Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg. 2017;1(2):105\u201313.","journal-title":"Ann Gastroenterol Surg"},{"key":"835_CR6","unstructured":"https:\/\/spectraldx.com\/spectral-medical-and-vantive-announce-topline-results-from-spectrals-tigris-trial-evaluating-pmxhemoadsorption-therapy-for-endotoxic-septic-shock\/"},{"issue":"3","key":"835_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/cc13912","volume":"18","author":"C Ronco","year":"2014","unstructured":"Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care. 2014;18(3):309.","journal-title":"Crit Care"},{"issue":"1","key":"835_CR8","doi-asserted-by":"publisher","first-page":"17600","DOI":"10.1038\/s41598-023-44850-9","volume":"13","author":"E Forin","year":"2023","unstructured":"Forin E, Lorenzoni G, Ferrer R, De Cal M, Zanella M, Marchionna N, et al. Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry. Sci Rep. 2023;13(1):17600.","journal-title":"Sci Rep"},{"key":"835_CR9","unstructured":"https:\/\/www.biospace.com\/press-releases\/spectral-medical-inc-announces-results-of-annual-meeting-of-shareholders"},{"key":"835_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000527708","volume":"200","author":"JA Kellum","year":"2023","unstructured":"Kellum JA, Shoji H, Foster DM, Walker PM. Adsorption of Endotoxin and Mitigation of Sepsis. Contrib Nephrol. 2023;200:133\u201341.","journal-title":"Contrib Nephrol"},{"key":"835_CR11","unstructured":"https:\/\/spectraldx.com\/tigris-trial-enrollment-completed\/"},{"issue":"23","key":"835_CR12","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"key":"835_CR13","doi-asserted-by":"crossref","unstructured":"Amaral AC. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009;302(18):1968\u20139. (author reply 1969\u201370).","DOI":"10.1001\/jama.2009.1607"},{"issue":"4","key":"835_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042228","volume":"22","author":"H Shoji","year":"2021","unstructured":"Shoji H, Opal SM. Therapeutic rationale for endotoxin removal with polymyxin B immobilized fiber column (PMX) for septic shock. Int J Mol Sci. 2021;22(4):2228.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"835_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975\u201384.","journal-title":"Intensive Care Med"},{"issue":"9","key":"835_CR16","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00134-015-3931-x","volume":"41","author":"M Antonelli","year":"2015","unstructured":"Antonelli M, Cutuli SL, Ronco C. Polymyxin B hemoperfusion in septic shock: just look at the evidence! Intensive Care Med. 2015;41(9):1731\u20132.","journal-title":"Intensive Care Med"},{"issue":"6","key":"835_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s00134-015-3801-6","volume":"41","author":"M Darmon","year":"2015","unstructured":"Darmon M, Bagshaw SM, Forni LG. Balancing the \u201chumors\u201d in severe sepsis: still a role for extracorporeal therapies? Intensive Care Med. 2015;41(6):1132\u20134.","journal-title":"Intensive Care Med"},{"key":"835_CR18","doi-asserted-by":"crossref","unstructured":"Antonelli M, Ronco C. Polymyxin B hemoperfusion in sepsis: growing body of evidence and occasional conflicting results. Blood Purif. 2015;39(1\u20133):I-II.","DOI":"10.1159\/000431018"},{"issue":"14","key":"835_CR19","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"1","key":"835_CR20","first-page":"3","volume":"38","author":"D Payen","year":"2019","unstructured":"Payen D. Haemoperfusion with polymyxin B membrane: recent results for an old debate! Anaesth Crit Care Pain Med. 2019;38(1):3\u20134.","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"12","key":"835_CR21","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205\u201312.","journal-title":"Intensive Care Med"},{"key":"835_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40560-019-0386-0","volume":"7","author":"T Iba","year":"2019","unstructured":"Iba T, Klein DJ. The wind changed direction and the big river still flows: from Euphrates to Tigris. J Intensive Care. 2019;7:31.","journal-title":"J Intensive Care"},{"issue":"2","key":"835_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00134-017-5004-9","volume":"44","author":"T Fujii","year":"2018","unstructured":"Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis\/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44(2):167\u201378.","journal-title":"Intensive Care Med"},{"issue":"3","key":"835_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/ALN.0000000000002820","volume":"131","author":"A Putzu","year":"2019","unstructured":"Putzu A, Schorer R, Lopez-Delgado JC, Cassina T, Landoni G. Blood purification and mortality in sepsis and septic shock: a systematic review and meta-analysis of randomized trials. Anesthesiology. 2019;131(3):580\u201393.","journal-title":"Anesthesiology"},{"issue":"12","key":"835_CR25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/CCM.0000000000005991","volume":"51","author":"JJ Chen","year":"2023","unstructured":"Chen JJ, Lai PC, Lee TH, Huang YT. Blood purification for adult patients with severe infection or sepsis\/septic shock: a network meta-analysis of randomized controlled trials. Crit Care Med. 2023;51(12):1777\u201389.","journal-title":"Crit Care Med"},{"issue":"3","key":"835_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/sur.2016.168","volume":"18","author":"T Terayama","year":"2017","unstructured":"Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis. Surg Infect (Larchmt). 2017;18(3):225\u201333.","journal-title":"Surg Infect (Larchmt)"},{"issue":"8","key":"835_CR27","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/CCM.0000000000002362","volume":"45","author":"T Chang","year":"2017","unstructured":"Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, et al. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017;45(8):e858\u201364.","journal-title":"Crit Care Med"},{"issue":"1","key":"835_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0178-9","volume":"6","author":"SL Cutuli","year":"2016","unstructured":"Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, et al. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6(1):77.","journal-title":"Ann Intensive Care"},{"key":"835_CR29","doi-asserted-by":"crossref","unstructured":"Nakamura Y, Kitamura T, Kiyomi F, Hayakawa M, Hoshino K, Kawano Y, Yamasaki R, Nishida T, Mizunuma M, Ishikura H. Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Crit Care. 2017;21(1):134.","DOI":"10.1186\/s13054-017-1712-3"},{"issue":"1","key":"835_CR30","doi-asserted-by":"publisher","first-page":"24132","DOI":"10.1038\/s41598-021-03055-8","volume":"11","author":"WY Lee","year":"2021","unstructured":"Lee WY, Kim HJ, Kim EY. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study. Sci Rep. 2021;11(1):24132.","journal-title":"Sci Rep"},{"issue":"1","key":"835_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s44158-022-00056-5","volume":"2","author":"H Shoji","year":"2022","unstructured":"Shoji H, Ferrer R. Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action. J Anesth Analg Crit Care. 2022;2(1):27.","journal-title":"J Anesth Analg Crit Care"},{"issue":"7","key":"835_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071023","volume":"13","author":"S Garcia-Ramos","year":"2023","unstructured":"Garcia-Ramos S, Caama\u00f1o E, Rodr\u00edguez Ben\u00edtez P, Benito P, Calvo A, Ramos S, et al. Mortality risk prediction in abdominal septic shock treated with polymyxin-B hemoperfusion: a retrospective cohort study. J Pers Med. 2023;13(7):1023.","journal-title":"J Pers Med"},{"key":"835_CR33","unstructured":"https:\/\/spectraldx.com\/february-tigris-trial-update\/"},{"key":"835_CR34","unstructured":"https:\/\/www.globenewswire.com\/news-release\/2025\/04\/16\/3062422\/0\/en\/Spectral-Medical-Completes-Tigris-Trial-Enrollment.html"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-025-00835-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:55:12Z","timestamp":1767056112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40560-025-00835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1186\/s40560-025-00835-6","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TI participated on advisory boards of Japan Blood Products Organization, Asahi Kasei Pharmaceuticals, and Toray Medical.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}